Back to trial detailsIntake questionnaire
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Applying to HonorHealth Research and Innovation Institute · Scottsdale, Arizona
Answer a few short questions to share with the research team.
0 of 4 answered